Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Monday

Allogene Therapeutics (NASDAQ:ALLO) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $0.00 million for the quarter.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Trading Down 1.7 %

ALLO opened at $1.16 on Friday. Allogene Therapeutics has a 1-year low of $1.09 and a 1-year high of $3.78. The company has a market cap of $253.70 million, a price-to-earnings ratio of -0.74 and a beta of 0.60. The company’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $1.97.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ALLO shares. HC Wainwright dropped their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 19th. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Insider Buying and Selling

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 61,757 shares of company stock worth $115,873. Insiders own 24.30% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).